Immunovaccine, a Nova Scotia, Canada-headquartered clinical-stage immunotherapy and vaccine company, is expanding its collaboration with Leidos, a science and technology company, to develop preventative, peptide-based malaria vaccine candidates.

The United States Agency for International Development (USAID) supported an initial collaboration via a Leidos Malaria Vaccine Development Program sub-contract, according to Immunovaccine. As one of the preferred formulations for further development under a new contract extension, Leidos and USAID selected Immunovaccine’s DepoVax-based platform, which is designed to extend exposure of the immune system to an antigen and adjuvant combination. Under the new subcontract, the collaborators plan to conduct additional research that focuses on identifying the most promising target-formulation combinations.

Source: Immunovaccine